171
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      Journal of Clinical Immunology
      Springer US
      Chronic mucocutaneous candidiasis, CMC, primary immunodeficiency, PID, signal transducer and activator of transcription 1, STAT1, gain-of-function, GOF, phosphorylation
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 ( STAT1) result in unbalanced STAT signaling and cause immune dysregulation and immunodeficiency. The latter is often characterized by the susceptibility to recurrent Candida infections, resulting in the clinical picture of chronic mucocutaneous candidiasis (CMC). This study aims to assess the frequency of GOF STAT1 mutations in a large international cohort of CMC patients.

          Methods

          STAT1 was sequenced in genomic DNA from 57 CMC patients and 35 healthy family members. The functional relevance of nine different STAT1 variants was shown by flow cytometric analysis of STAT1 phosphorylation in patients’ peripheral blood cells (PBMC) after stimulation with interferon (IFN)-α, IFN-γ or interleukin-27 respectively. Extended clinical data sets were collected and summarized for 26 patients.

          Results

          Heterozygous mutations within STAT1 were identified in 35 of 57 CMC patients (61 %). Out of 39 familial cases from 11 families, 26 patients (67 %) from 9 families and out of 18 sporadic cases, 9 patients (50 %) were shown to have heterozygous mutations within STAT1. Thirteen distinct STAT1 mutations are reported in this paper. Eight of these mutations are known to cause CMC (p.M202V, p.A267V, p.R274W, p.R274Q, p.T385M, p.K388E, p.N397D, and p.F404Y). However, five STAT1 variants (p.F172L, p.Y287D, p.P293S, p.T385K and p.S466R) have not been reported before in CMC patients.

          Conclusion

          STAT1 mutations are frequently observed in patients suffering from CMC. Thus, sequence analysis of STAT1 in CMC patients is advised. Measurement of IFN- or IL-induced STAT1 phosphorylation in PBMC provides a fast and reliable diagnostic tool and should be carried out in addition to genetic testing.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          IL-17 and Th17 Cells.

          CD4+ T cells, upon activation and expansion, develop into different T helper cell subsets with different cytokine profiles and distinct effector functions. Until recently, T cells were divided into Th1 or Th2 cells, depending on the cytokines they produce. A third subset of IL-17-producing effector T helper cells, called Th17 cells, has now been discovered and characterized. Here, we summarize the current information on the differentiation and effector functions of the Th17 lineage. Th17 cells produce IL-17, IL-17F, and IL-22, thereby inducing a massive tissue reaction owing to the broad distribution of the IL-17 and IL-22 receptors. Th17 cells also secrete IL-21 to communicate with the cells of the immune system. The differentiation factors (TGF-beta plus IL-6 or IL-21), the growth and stabilization factor (IL-23), and the transcription factors (STAT3, RORgammat, and RORalpha) involved in the development of Th17 cells have just been identified. The participation of TGF-beta in the differentiation of Th17 cells places the Th17 lineage in close relationship with CD4+CD25+Foxp3+ regulatory T cells (Tregs), as TGF-beta also induces differentiation of naive T cells into Foxp3+ Tregs in the peripheral immune compartment. The investigation of the differentiation, effector function, and regulation of Th17 cells has opened up a new framework for understanding T cell differentiation. Furthermore, we now appreciate the importance of Th17 cells in clearing pathogens during host defense reactions and in inducing tissue inflammation in autoimmune disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis

            The commensal fungus Candida albicans causes oropharyngeal candidiasis (OPC; thrush) in settings of immunodeficiency. Although disseminated, vaginal, and oral candidiasis are all caused by C. albicans species, host defense against C. albicans varies by anatomical location. T helper 1 (Th1) cells have long been implicated in defense against candidiasis, whereas the role of Th17 cells remains controversial. IL-17 mediates inflammatory pathology in a gastric model of mucosal candidiasis, but is host protective in disseminated disease. Here, we directly compared Th1 and Th17 function in a model of OPC. Th17-deficient (IL-23p19−/−) and IL-17R–deficient (IL-17RA−/−) mice experienced severe OPC, whereas Th1-deficient (IL-12p35−/−) mice showed low fungal burdens and no overt disease. Neutrophil recruitment was impaired in IL-23p19−/− and IL-17RA−/−, but not IL-12−/−, mice, and TCR-αβ cells were more important than TCR-γδ cells. Surprisingly, mice deficient in the Th17 cytokine IL-22 were only mildly susceptible to OPC, indicating that IL-17 rather than IL-22 is vital in defense against oral candidiasis. Gene profiling of oral mucosal tissue showed strong induction of Th17 signature genes, including CXC chemokines and β defensin-3. Saliva from Th17-deficient, but not Th1-deficient, mice exhibited reduced candidacidal activity. Thus, the Th17 lineage, acting largely through IL-17, confers the dominant response to oral candidiasis through neutrophils and antimicrobial factors.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.

              Chronic mucocutaneous candidiasis disease (CMCD) is characterized by recurrent or persistent infections of the skin, nails, and oral and genital mucosae caused by Candida albicans and, to a lesser extent, Staphylococcus aureus, in patients with no other infectious or autoimmune manifestations. We report two genetic etiologies of CMCD: autosomal recessive deficiency in the cytokine receptor, interleukin-17 receptor A (IL-17RA), and autosomal dominant deficiency of the cytokine interleukin-17F (IL-17F). IL-17RA deficiency is complete, abolishing cellular responses to IL-17A and IL-17F homo- and heterodimers. By contrast, IL-17F deficiency is partial, with mutant IL-17F-containing homo- and heterodimers displaying impaired, but not abolished, activity. These experiments of nature indicate that human IL-17A and IL-17F are essential for mucocutaneous immunity against C. albicans, but otherwise largely redundant.
                Bookmark

                Author and article information

                Contributors
                0761 - 270-77731 , bodo.grimbacher@uniklinik-freiburg.de
                Journal
                J Clin Immunol
                J. Clin. Immunol
                Journal of Clinical Immunology
                Springer US (New York )
                0271-9142
                1573-2592
                25 November 2015
                25 November 2015
                2016
                : 36
                : 73-84
                Affiliations
                [ ]Center for Chronic Immunodeficiency, University Medical Center Freiburg, Engesser Straße 4, 79108 Freiburg, Germany
                [ ]Faculty of Biology, University of Freiburg, Freiburg, Germany
                [ ]Addenbrooke’s Hospital, Cambridge, UK
                [ ]University of Alabama at Birmingham, Birmingham, USA
                [ ]Helios Kliniken, Childrens Hospital, Krefeld, Germany
                [ ]Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
                [ ]Medical University of Hannover, Hannover, Germany
                [ ]Group of Primary Immunodeficiencies, Universidad de Antioquia, Medellin, Colombia
                [ ]Division of Pediatric Allergy and Clinical Immunology, McGill University Health Center, Montreal, QC Canada
                [ ]University of São Paulo, São Paulo, Brazil
                [ ]Immunology Day Centre, Royal Group of Hospitals, Belfast, UK
                [ ]Queen’s University Belfast, Belfast, UK
                [ ]Child Life and Health, University of Edinburgh, Edinburgh, UK
                [ ]Department of Paediatric Gastroenterology, Royal Hospital for Sick Children, Glasgow, UK
                [ ]Department of Genetics, Aarhus University Hospital, Aarhus, Denmark
                [ ]Royal Free Hospital, University College London, London, UK
                [ ]Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
                [ ]Department of Microbiology and Immunology, Experimental Laboratory Immunology, Katholieke Universiteit Leuven, Leuven, Belgium
                [ ]Center for Diagnosis and Treatment of Primary Immunodeficiencies, Department of Pediatrics, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovak Republic
                [ ]Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                [ ]Immuno Deficiency Center Leipzig, Clinic St. Georg, Leipzig, Germany
                [ ]Translational Centre for Regenerative Medicine, University Leipzig, Leipzig, Germany
                [ ]Division of Rheumatology and Immunology, Children’s Hospital Central California, Madera, CA USA
                [ ]University of Washington and Seattle Children’s Research Institute, Seattle, WA USA
                [ ]Department of Pediatrics and Immunology, University of Washington, Seattle, WA USA
                [ ]DZIF Center, Standort Freiburg, Germany
                Article
                214
                10.1007/s10875-015-0214-9
                4718942
                26604104
                c6b0e2d6-6eea-430b-8a70-7d6f1bab7476
                © The Author(s) 2015

                Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

                History
                : 20 June 2014
                : 9 June 2015
                Categories
                Original Research
                Custom metadata
                © Springer Science+Business Media New York 2016

                Immunology
                chronic mucocutaneous candidiasis,cmc,primary immunodeficiency,pid,signal transducer and activator of transcription 1,stat1,gain-of-function,gof,phosphorylation

                Comments

                Comment on this article